Study to Assess Bronchospasm Potentially Induced by Next-Generation Propellant vs HFA Propellant in an MDI in Participants With Well/Partially Controlled Asthma

PHASE3CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

May 2, 2023

Primary Completion Date

August 21, 2023

Study Completion Date

August 21, 2023

Conditions
Asthma
Interventions
DRUG

HFA MDI

"* Dose formulation: MDI~* Unit dose strength(s): Reference (propellant only)~* Dosage Level: 4 inhalations, single dose~* Route of administration: Oral inhalation~* Participants will receive treatment A in 1 or 2 possible sequences AB or BA"

DRUG

HFO MDI

"* Dose formulation: MDI~* Unit dose strength(s): Experimental (propellant only)~* Dosage Level: 4 inhalations, single dose~* Route of administration: Oral inhalation~* Participants will receive treatment A in 1 or 2 possible sequences AB or BA"

Trial Locations (4)

27607

Research Site, Raleigh

63141

Research Site, St Louis

79903

Research Site, El Paso

02747

Research Site, North Dartmouth

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY